RVL Pharmaceuticals plc (OTCPK: RVLP.Q)
Health Care · Pharmaceuticals · US
$0.00
— today · 0.0% 1Y
RVL Pharmaceuticals plc (OTCPK: RVLP.Q) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $111.00 and employs 125 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores RVL Pharmaceuticals plc across four factors: quality 28/100, value 51/100, growth 0/100. Its strongest factor is value.
RVLP.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $111.00
- Revenue (TTM)
- $36.92M
- P/E
- —
- EPS
- -0.70
- Dividend yield
- —
- Beta (5Y)
- 43.18
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 111.41M
- Employees
- 125
- Next earnings
- —
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
- ISIN
- IE00BF2HDL56
- Listed since
- Oct 19, 2018
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.